Compare Stocks → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ARCTNASDAQ:AVDLNASDAQ:CALANASDAQ:CERCOTCMKTS:NWBO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$27.64-8.3%$35.61$17.52▼$43.81$744.07M2.6455,471 shs609,090 shsAVDLAvadel Pharmaceuticals$17.99-0.6%$15.43$9.50▼$18.85$1.63B1.61.24 million shs1.61 million shsCALACalithera Biosciences$0.04-20.0%$0.03$0.01▼$0.50$195K-0.171,618 shs5,257 shsCERCCerecor$15.94+4.6%$2.60$1.98▼$4.50$1.53B1.441.27 million shs222,087 shsNWBONorthwest Biotherapeutics$0.50$0.54$0.40▼$1.09$608.28M-0.681.71 million shs1.25 million shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics-8.26%-13.19%-16.57%-14.35%-0.86%AVDLAvadel Pharmaceuticals-0.55%+11.39%+14.08%+19.61%+78.65%CALACalithera Biosciences-20.00%+100.00%+100.00%+28.00%-23.08%CERCCerecor0.00%+5.84%+259.01%+288.78%+465.25%NWBONorthwest Biotherapeutics-0.87%-5.45%-3.45%-14.63%-9.17%Top 5 AI Stocks to Buy for 2024 (Ad)5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCTArcturus Therapeutics1.8036 of 5 stars3.50.00.00.02.53.30.6AVDLAvadel Pharmaceuticals3.077 of 5 stars4.52.00.00.03.11.70.6CALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACERCCerecorN/AN/AN/AN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics3.00Buy$61.33121.90% UpsideAVDLAvadel Pharmaceuticals3.00Buy$22.5725.47% UpsideCALACalithera BiosciencesN/AN/AN/AN/ACERCCerecorN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest ARCT, AVDL, CERC, CALA, and NWBO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.003/20/2024ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.003/8/2024ARCTArcturus TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/5/2024AVDLAvadel PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.003/5/2024AVDLAvadel PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$18.00 ➝ $23.003/5/2024AVDLAvadel PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$27.00 ➝ $29.003/5/2024AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $25.003/5/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.002/8/2024ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $48.002/6/2024AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$169.93M4.38N/AN/A$10.42 per share2.65AVDLAvadel Pharmaceuticals$27.96M58.28N/AN/A$0.98 per share18.36CALACalithera Biosciences$9.75M0.02N/AN/A($0.40) per share-0.10CERCCerecor$6.70M228.42N/AN/A$0.22 per share72.45NWBONorthwest Biotherapeutics$1.93M312.43N/AN/A($0.06) per share-8.35Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$29.73M-$1.04N/A5.42N/A-15.65%-18.22%-11.95%5/14/2024 (Estimated)AVDLAvadel Pharmaceuticals-$160.28M-$2.04N/A21.67N/AN/A-198.06%-84.51%5/2/2024 (Estimated)CALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/ACERCCerecor-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/ANWBONorthwest Biotherapeutics-$62.60M-$0.06N/A∞N/A-3,240.11%N/A-207.51%5/8/2024 (Estimated)Latest ARCT, AVDL, CERC, CALA, and NWBO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ARCTArcturus Therapeutics-$1.69-$0.32+$1.37-$0.32$64.14 million$33.99 million3/5/2024Q4 2023NWBONorthwest BiotherapeuticsN/A-$0.02-$0.02-$0.02N/A$0.45 million3/4/2024Q4 2023AVDLAvadel Pharmaceuticals-$0.28-$0.32-$0.04-$0.29$17.41 million$19.45 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/ACERCCerecorN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A4.724.72AVDLAvadel PharmaceuticalsN/A3.643.36CALACalithera BiosciencesN/AN/AN/ACERCCerecor0.792.192.18NWBONorthwest BiotherapeuticsN/A0.090.09OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%AVDLAvadel Pharmaceuticals69.19%CALACalithera BiosciencesN/ACERCCerecor62.84%NWBONorthwest Biotherapeutics0.04%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics13.80%AVDLAvadel Pharmaceuticals4.00%CALACalithera Biosciences6.60%CERCCerecor45.70%NWBONorthwest Biotherapeutics9.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18026.92 million23.20 millionOptionableAVDLAvadel Pharmaceuticals15490.58 million86.95 millionOptionableCALACalithera Biosciences84.87 million4.55 millionNot OptionableCERCCerecor3196.01 millionN/ANot OptionableNWBONorthwest Biotherapeutics251.20 billion1.09 billionNot OptionableARCT, AVDL, CERC, CALA, and NWBO HeadlinesSourceHeadlineNorthwest Biotherapeutics (OTCMKTS:NWBO) Stock Passes Below 200-Day Moving Average of $0.67americanbankingnews.com - April 16 at 3:34 AMNorthwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directorsprnewswire.com - March 21 at 11:09 AM‘Spoofing’ case might draw back curtain on high-speed trading firmsft.com - March 2 at 10:11 AMNorthwest Biotherapeutics, Inc. (NWBO)uk.finance.yahoo.com - February 29 at 2:53 PMNorthwest Biotherapeutics Stock (OTC:NWBO), Short Interest Reportbenzinga.com - February 23 at 12:07 AMNorthwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certificationfinance.yahoo.com - February 7 at 4:37 PMNorthwest Biotherapeutics submits marketing application to UK MHRA for DCVax-Lmsn.com - December 22 at 10:28 AMNorthwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax-L For Glioblastomafinanznachrichten.de - December 21 at 12:53 PMNorthwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastomafinance.yahoo.com - December 21 at 12:53 PMNorthwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Applicationfinance.yahoo.com - November 22 at 2:22 PMNorthwest Biotherapeutics Inc NWBOmorningstar.com - October 31 at 12:12 PMNorthwest Bio: Another Small Filing Delaymsn.com - October 14 at 10:44 AMNW Bio dips on announcing delay in submission of marketing application for DCVaxseekingalpha.com - October 13 at 12:56 PMNorthwest Biotherapeutics Shares Slide on Application Delaymarketwatch.com - October 13 at 12:56 PMNorthwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Applicationfinance.yahoo.com - October 13 at 12:56 PMPolice searching for suspects in Northwest DC shootingwjla.com - October 10 at 10:28 AMNorthwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Boardfinance.yahoo.com - September 12 at 6:48 PMSports Betting In The Northwest Territories- Is it Legal? Best Sportsbooks In The NWTbasketballinsiders.com - August 30 at 6:42 PMNorthwest Bio: Is There Ever Going To Be A Right Time?msn.com - August 17 at 9:29 PMNorthwest Missouri State Universityusnews.com - August 6 at 5:59 PMNorthwest Hospitalhealth.usnews.com - August 4 at 6:51 PMStanding Stone Circles: The most ancient builders of Northwest Arabianationalgeographic.com - August 3 at 8:41 AMSiloam Springs Newsnwaonline.com - July 22 at 1:52 PMWhy Northwest Bio Is Shunned by Savvy Health Care Investorsthestreet.com - July 15 at 2:20 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsArcturus TherapeuticsNASDAQ:ARCTArcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Avadel PharmaceuticalsNASDAQ:AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Calithera BiosciencesNASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.CerecorNASDAQ:CERCCerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.Northwest BiotherapeuticsOTCMKTS:NWBONorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.